Safety and Efficacy of LY3454738 in Healthy Participants and Atopic Dermatitis

Phase 1, randomised, triple-blind trial of ucenprubart in atopic dermatitis (AD) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration and Number of Participants Achieving a Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 with a >= 2-point Improvement from Baseline at Week 12. Started Nov 2018; status: completed.